With the second half of the year underway, Oppenheimer is highlighting what it calls its top small- and midcap seasonal standout investment ideas. Smallcap stocks have underperformed the S & P 500 this year, with the Russell 2000 virtually unchanged, up a scant 0.12% through Tuesday. The broad market index, however, has advanced around 17%. Midcaps haven't done much better, with the S & P 400 MidCap higher by only 3.8% in 2024.
mountain Viking Therapeutics, year-to-date Oppenheimer's bullish view of Viking rests on a possible "best-in-class profile" for both the oral dosage and subcutaneous injection of the company's GLP-1 and GIP dual agonists VK2735.
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む: